In January 2011, Synosia Therapeutics announced its intention to merge with the Finnish biotech company Biotie Therapies. The merger was completed on 5th February 2011, and the group name was changed to Biotie Therapies.
Synosis Therapeutics is a CNS-focused development company using the latest technologies to advance molecules through phase 1 and 2 clinical trials. As head of the operations function I am involved in establishing relationships with clinical trial sites as well as with our biotech & pharma partners.